Dupont, A.-C.; Arlicot, N.; Vercouillie, J.; Serrière, S.; Maia, S.; Bonnet-Brilhault, F.; Santiago-Ribeiro, M.-J.
Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks. Pharmaceuticals 2023, 16, 1127.
https://doi.org/10.3390/ph16081127
AMA Style
Dupont A-C, Arlicot N, Vercouillie J, Serrière S, Maia S, Bonnet-Brilhault F, Santiago-Ribeiro M-J.
Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks. Pharmaceuticals. 2023; 16(8):1127.
https://doi.org/10.3390/ph16081127
Chicago/Turabian Style
Dupont, Anne-Claire, Nicolas Arlicot, Johnny Vercouillie, Sophie Serrière, Serge Maia, Frédérique Bonnet-Brilhault, and Maria-Joao Santiago-Ribeiro.
2023. "Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks" Pharmaceuticals 16, no. 8: 1127.
https://doi.org/10.3390/ph16081127
APA Style
Dupont, A.-C., Arlicot, N., Vercouillie, J., Serrière, S., Maia, S., Bonnet-Brilhault, F., & Santiago-Ribeiro, M.-J.
(2023). Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks. Pharmaceuticals, 16(8), 1127.
https://doi.org/10.3390/ph16081127
